PCN66 Cost-Effectiveness of Denosumab Versus Zoledronic Acid for Skeletal-Related Event (SRE) Reduction in Bone-Metastatic Prostate Cancer (mPC) in the UK
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.2106
https://www.valueinhealthjournal.com/article/S1098-3015(12)03820-X/fulltext
Title :
PCN66 Cost-Effectiveness of Denosumab Versus Zoledronic Acid for Skeletal-Related Event (SRE) Reduction in Bone-Metastatic Prostate Cancer (mPC) in the UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03820-X&doi=10.1016/j.jval.2012.08.2106
First page :
A420
Section Title :
Cancer
Open access? :
No
Section Order :
759